CONTRACEPTIVE JAB UNDER FIRE AGAIN – Various study find Depo Provera can be linked to tripled brain tumour risk
A widely used contraceptive injection has once again come under fire, as new research reveals it may significantly increase the risk of developing a potentially fatal brain tumour.
According to a series of recent studies, women using me-droxy-pro-gest-erone acetate, commonly sold under the brand name Depo Provera, are more than three times as likely to develop a menin-gioma—the most common type of brain tumour—when used f or 12 months or more. This marks the third major investigation in just over a year linking the contraceptive jab to serious health risks.
The alarming findings have prompted hundreds of UK women to consider legal action against the manufacturer, Pfizer, for allegedly failing to adequately warn users of the risks. Meanwhile, a class action lawsuit involving over 500 women is already underway in the U.S., targeting both Pfizer and generic producers.
In England alone, over 10,000 prescriptions for Depo Provera are issued each month, with the jab often recommended for long-term birth control. However, new evidence is now raising serious concerns.
The latest study, published in Expert Opinion on Drug Safety by researchers at the University of British Columbia, examined over 72,000 women on the jab compared to 247,000 on oral contraceptives, and confirmed that the risk of meningioma was more than tripled in long-term users of the injection.
This follows a 2024 study published in the British Medical Journal involving over 18,000 women, conducted by the French National Agency for Medicines and Health Products Safety, which concluded that women on Depo Provera for more than a year were up to five times more likely to develop a meningioma. Another 2023 study from the University of Alabama found similar results.
